What the newer draft says
HHS is short for the U.S. Department of Health and Human Services. Epitalon’s draft policy came from HHS on October 30, 2026. HHS describes a plan to take no action over certain compounding that meets every condition. This is a stated plan about enforcement, not a change in what the law allows.
Compounding is when a pharmacist or physician makes a drug to meet a person’s need, instead of using a finished factory product.
The draft applies to doctors and pharmacies licensed by a state. It concerns a drug with just one active ingredient, the part meant to have a treatment effect, made for a person named on a prescription. For compounding that fills an individual prescription, section 503A of federal law sets further conditions. Those legal conditions still apply.
The six named peptides are epitalon, KPV, semax, MOTS-c, BPC-157, and TB-500. The draft has ten conditions, as well as limits for each substance. Ask the pharmacist to go through the linked draft with you and show how every condition would be met; a license and a prescription alone do not settle that. A blend, which combines active ingredients, is not covered. Nor are 503B outsourcing facilities: businesses registered with FDA to make drug batches, often for clinics and hospitals, without needing prescriptions that name individual patients. Ask the pharmacy whether it is working under 503A or is a registered 503B facility.
Appendix B, the draft’s section with limits for each substance, names epitalon acetate. Acetate identifies the particular chemical form covered here; the shorter name epitalon does not by itself identify that form. It describes shots under the skin or into muscle, in courses separated by breaks. The draft also calls for a certificate of analysis, a document about testing. It does not cover every form of this peptide.
The policy stays a draft that is not legally binding on HHS or the public. The stated plan not to act is not an enforceable promise. It grants no right to make a drug, leaves the law and FDA lists unchanged, and gives no drug FDA approval.
What the committee account adds
An FDA advisory panel discussed epitalon on July 24, 2026. HHS’s later account says the panel backed its addition to the list for compounding.
Before the meeting, FDA staff had argued in writing against adding it. Staff found too little evidence that it works for insomnia, meaning trouble sleeping.
The later account of support is real. But panel advice cannot change the list; that takes formal rulemaking, a process that allows public comment.
So a headline about a favorable vote cannot stand alone as the answer to whether a particular medicine has been approved. The source, the kind of decision, and what changed all matter. Keep the committee account beside the separate draft and the still-unchanged ingredient list. That makes room for the later information without overstating it.
Why withdrawn does not mean cleared
FDA has a page about raw ingredients used to make pharmacy-mixed drugs. On that page, whose stated current date is April 22, 2026, epitalon appears among requests that were withdrawn from consideration. Its safety concerns remain printed with the entry.
A nomination puts an ingredient forward for FDA to consider. Taking that request back does not clear it for use. FDA gives no date for when epitalon’s request was taken back.
FDA’s official list of additional raw ingredients for compounding is called the 503A bulks list. It contained none of the HHS draft’s six peptides as of November 3, 2026.
For a specific offer, ask the doctor or other prescriber which current rule or policy they rely on and how its conditions are met. Ask the pharmacy to name the exact drug and ingredient form it can provide, then show how that medicine meets the policy’s limits. Ask the prescriber what evidence supports using it for your concern; ask the pharmacist about the medicine’s identity and testing. An explanation of the policy alone does not answer those questions.